文献速递浆细胞疾病

单克隆免疫球蛋白分泌状态与骨髓瘤患者结局相关:一项回顾性研究

Secretory status of monoclonal immunoglobulin is related to the outcome of patients with myeloma: a retrospective study.
PubMed 文献 · Blood Adv · 2019-01-01

该回顾性研究分析822例接受硼替佐米或沙利度胺方案的新诊断多发性骨髓瘤患者,按单克隆免疫球蛋白分泌状态分为可测量病与不可测量病(寡分泌、非分泌、不产生型)。可测量病患者中位无进展生存期和总生存期均显著长于不可测量病各亚型,且硼替佐米较沙利度胺显著改善可测量病患者的无进展生存期和总生存期,但未改善不可测量病患者。

要点

  • 可测量病中位无进展生存期27个月、总生存期51个月,均显著优于寡分泌、非分泌及不产生型。
  • 不可测量病中不产生型骨髓瘤的无进展生存期和总生存期最短,均为2.0个月。
  • 可测量病患者中硼替佐米较沙利度胺显著改善无进展生存期和总生存期,不可测量病中无显著差异。

核心结论

  • 硼替佐米方案在不可测量型多发性骨髓瘤患者中的疗效不优于沙利度胺方案。
  • 研究结果需在其他患者队列中确认,最好在前瞻性试验背景下进行。

研究设计与样本

  • 回顾性研究,分析822例接受硼替佐米或沙利度胺为基础方案的新诊断多发性骨髓瘤患者。
  • 按单克隆免疫球蛋白分泌状态分为可测量病与不可测量病,不可测量病包括寡分泌、非分泌和不产生型骨髓瘤。

主要发现

  • 可测量病、寡分泌、非分泌和不产生型患者的中位无进展生存期分别为27、18、19和2.0个月(P < .001)。
  • 可测量病、寡分泌、非分泌和不产生型患者的中位总生存期分别为51、30、22和2.0个月(P < .001)。
  • 不可测量病组中,不产生型骨髓瘤患者的中位无进展生存期和总生存期最短。
  • 可测量病患者中,硼替佐米组与沙利度胺组的中位无进展生存期分别为33和25个月(P = .022),中位总生存期分别为58和41个月(P < .001)。
  • 不可测量病患者中,硼替佐米组与沙利度胺组的中位无进展生存期分别为16和18个月(P = .617),中位总生存期分别为27和22个月(P = .743)。

关键数值与推荐

  • 可测量病、寡分泌、非分泌和不产生型患者的中位无进展生存期分别为27、18、19和2.0个月(P < .001)。
  • 可测量病、寡分泌、非分泌和不产生型患者的中位总生存期分别为51、30、22和2.0个月(P < .001)。
  • 可测量病患者中,硼替佐米组与沙利度胺组的中位无进展生存期分别为33和25个月(P = .022),中位总生存期分别为58和41个月(P < .001)。
  • 不可测量病患者中,硼替佐米组与沙利度胺组的中位无进展生存期分别为16和18个月(P = .617),中位总生存期分别为27和22个月(P = .743)。

临床怎么用

  • 作者指出,基于硼替佐米的治疗在不可测量型多发性骨髓瘤患者中表现不优于基于沙利度胺的治疗。
  • 作者认为研究结果需在其他患者队列中确认,最好在前瞻性试验背景下进行。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The treatment of multiple myeloma (MM) with proteasome inhibitor (PI) bortezomib has significantly improved the survival of patients with MM. The 26S proteasome inhibitor targets the unfolded protein response (UPR) by inhibiting proteasome degradation of ubiquitinated paraprotein, subsequently leading to the lethal accumulation of paraprotein within the endoplasmic reticulum. According to secretory status of monoclonal immunoglobulin, newly diagnosed MM (NDMM) is divided into measurable and unmeasurable disease, which includes oligosecretory, nonsecretory, and nonproducer myeloma. The present study analyzed the clinical characteristics of 822 patients with NDMM who had either measurable or unmeasurable diseases and received bortezomib- or thalidomide-based therapies. Our results showed that the median progression-free survival (PFS) and overall survival (OS) of patients with MM was significantly longer in patients with measurable disease than those in oligosecretory, nonsecretory, and nonproducer MM (PFS: 27, 18, 19, and 2.0 months, respectively [P < .001]; OS: 51, 30, 22, and 2.0 months, respectively [P < .001]). Within the unmeasurable group, patients with nonproducer myeloma showed the shortest PFS and OS. Importantly, compared with thalidomide treatment, bortezomib significantly improved the PFS and OS of patients with MM with measurable disease (PFS: 25 and 33 months [P = .022], respectively; OS: 41 and 58 months [P < .001], respectively), but not those with unmeasurable disease (PFS: 18 and 16 months [P = .617], respectively; OS: 22 and 27 months [P = .743], respectively). Our results indicate that bortezomib-based therapy performed no better than thalidomide-based treatment in patients with unmeasurable MM. The results need to be confirmed in other patient cohorts, preferably in the context of a prospective trial.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Qin XQ, An G, Li ZJ, et al. Secretory status of monoclonal immunoglobulin is related to the outcome of patients with myeloma: a retrospective study. Blood Adv. 2019. PMID: 30833275. doi:10.1182/bloodadvances.2018019851

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。